They found no significant increase in risk in those using GLP-1 agonist therapy
This timing matters for women planning fertility treatment or natural conception
In July 2023, the FDA announced it was reviewing reports of stomach paralysis associated with GLP-1 drugs, including Ozempic and Wegovy
can represent Dallas-Fort Worth clients in lawsuits for any of the GLP-1 products listed above
Prior studies have produced mixed results, with some reporting elevated risk and others finding weaker or null associations. Variations in study design, patient populations, follow-up duration and analytic methods likely contribute to these discrepancies
Propensity score matching (1:1 ratio) was performed based on age, sex, baseline BMI, diabetes duration, and comorbidities